IKS

Inventurus Knowledge Solutions Share Price

₹1,538.85 +58.1 (3.92%)

27 Mar, 2025 13:37

SIP TrendupStart SIP in IKS

Start SIP

Performance

  • Low
  • ₹1,481
  • High
  • ₹1,542
  • 52 Week Low
  • ₹1,407
  • 52 Week High
  • ₹2,189
  • Open Price₹1,488
  • Previous Close₹1,481
  • Volume172,839

Investment Returns

  • Over 1 Month -19.65%
  • Over 3 Month -28.28%
  • Over 6 Month + 15.79%
  • Over 1 Year + 15.79%
SIP Lightning

Smart Investing Starts Here Start SIP with Inventurus Knowledge Solutions for Steady Growth!

Invest Now

Inventurus Knowledge Solutions Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 65.7
  • PEG Ratio
  • -
  • Market Cap Cr
  • 26,403
  • P/B Ratio
  • 22.8
  • Average True Range
  • 87.95
  • EPS
  • 23.42
  • Dividend Yield
  • 0
  • MACD Signal
  • -64.29
  • RSI
  • 34.95
  • MFI
  • 30.78

Inventurus Knowledge Solutions Financials

Inventurus Knowledge Solutions Technicals

EMA & SMA

Current Price
₹1,538.85
+ 58.1 (3.92%)
pointer
  • stock-down_img
  • Bearish Moving Average 7
  • stock-up_img
  • Bullish Moving Average 4
  • 20 Day
  • ₹1,602.64
  • 50 Day
  • ₹1,712.93
  • 100 Day
  • -
  • 200 Day
  • -

Resistance and Support

1491.97 Pivot Speed
  • R3 1,560.68
  • R2 1,541.52
  • R1 1,511.13
  • S1 1,461.58
  • S2 1,442.42
  • S3 1,412.03

What's your outlook on Inventurus Knowledge Solutions?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

IKS Health provides care enablement services through its advanced platform, easing administrative, clinical, and operational tasks for healthcare providers. Serving U.S. clients, its solutions include Revenue Cycle Management, Clinical Support, and Value-Based Care to enhance healthcare delivery.

Inventurus Knowledge Solutions Ltd has an operating revenue of Rs. 2,560.00 Cr. on a trailing 12-month basis. An annual revenue growth of 75% is outstanding, Pre-tax margin of 24% is great, ROE of 31% is exceptional. The company has a debt to equity of 70%, which is bit higher. The stock from a technical standpoint is trading below to its key moving averages. It needs to take out these levels and stay above it to make any meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 27 which is a POOR score indicating inconsistency in earnings, a RS Rating of 30 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at B- which is evident from recent demand for the stock, Group Rank of 97 indicates it belongs to a poor industry group of Comml Svcs-Healthcare and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Inventurus Knowledge Solutions Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-05 Quarterly Results

Inventurus Knowledge Solutions F&O

Inventurus Knowledge Solutions Shareholding Pattern

63.72%
1.92%
0.34%
5.48%
0%
10.26%
18.28%

About Inventurus Knowledge Solutions

  • NSE Symbol
  • IKS
  • BSE Symbol
  • 544309
  • ISIN
  • INE115Q01022

Similar Stocks to Inventurus Knowledge Solutions

Inventurus Knowledge Solutions FAQs

Inventurus Knowledge Solutions share price is ₹1,538 As on 27 March, 2025 | 13:23

The Market Cap of Inventurus Knowledge Solutions is ₹26402.5 Cr As on 27 March, 2025 | 13:23

The P/E ratio of Inventurus Knowledge Solutions is 65.7 As on 27 March, 2025 | 13:23

The PB ratio of Inventurus Knowledge Solutions is 22.8 As on 27 March, 2025 | 13:23

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23